SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet (STRK) is drawing attention for its surging ecosystem growth, marked by increasing app revenue, user activity, and Total Value Locked. The community is actively discussing its unique position as a quantum-resistant Layer 2, leveraging advanced ZK-STARK technology to offer Bitcoin staking and a seamless user experience through native Account Abstraction, setting it apart from other scaling solutions.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is currently trending due to recent positive clinical data, including a sustained complete resolution of lung metastasis in a breast cancer patient, and a new NCI grant advancing its prostate cancer immunotherapy. However, community sentiment is sharply divided, with enthusiasm for the scientific breakthroughs tempered by widespread concern over a history of significant stock dilution and reverse splits. Discussions are heavily focused on the implications of recent public offerings and a reverse stock split, as the company seeks to fund its ongoing and promising clinical trials.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its highly dedicated community's relentless focus on building a real-world, permissionless brand, highlighted by ongoing product launches such as Kendu Spice and significant IRL initiatives. This unwavering commitment and 'Kendu Sendu' mindset are driving widespread bullish sentiment and active conversation across the crypto space.

The future is now. ZygoSwap a decentralized exchange (DEX) on the BNB Chain, providing a fully optimized and customizable trading for any BNB-listed tokens. Key Features: 1. Lowest swapping and trading fees. 2. $ZYGO holders receive 50% reduced fees on swaps and liquidity provision (no minimum holding required). 3. Zero fees for swapping or trading $ZYGO itself. 4. Ability to swap, buy, trade, and provide liquidity for any token on the BNB Chain. 5. Mobile-friendly interface for seamless on-the-go use. 6. ZSwap liquidity rewards token and staking options for additional earnings.  Benefits: 1. Cost-efficient for frequent traders and liquidity providers due to significantly lower fees. 2. Deflationary, Fees generated are used to buy back and burn $ZYGO &amp; $ZSWAP tokens. 3, Enhanced incentives for $ZYGO holders, including reduced costs and future rewards/staking yields. 4. Rewards for large swaps/buys and community engagement (e.g., airdrops for retweets/follows). 5. Optimized offering faster, cheaper transactions in the BNB Chain DeFi ecosystem.

ZygoSwap

ZygoSwap ($ZSWAP) is gaining significant community traction as users enthusiastically discuss its active development team and the operational ZygoSwap DEX. Many are highlighting its unique 'memetility' and perceived undervaluation as a micro-cap project offering practical utility, such as low-fee swaps. The strong engagement and ongoing building efforts are central to the bullish sentiment circulating within the community.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is actively discussed after committing to absorb the electricity costs for its expanding AI data centers, aiming to alleviate concerns about rising consumer utility bills and regulatory scrutiny. This development frames broader community debate on the company's AI monetization strategy and cloud growth, with many investors anticipating whether upcoming earnings will drive a significant rebound amidst its recent market underperformance.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after a major bank issued a "Sell" rating, citing concerns over shrinking profit margins despite its strong position in the AI server market. The community is sharply divided, with many viewing the downgrade as strategic manipulation to acquire cheaper shares ahead of anticipated strong earnings. Bulls highlight the company's critical role in AI infrastructure and robust revenue growth, while bears focus on profitability challenges and management's perceived missteps.

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Campbell, CA.

Semler Scientific Inc

Semler Scientific is trending due to its imminent shareholder vote on a transformative merger with Strive, aiming to establish one of the largest public Bitcoin treasury companies. Community discussion focuses on the proposed share exchange and the combined entity's substantial Bitcoin holdings, weighing potential arbitrage against historical volatility and concerns regarding dilution and management. Investors are actively debating the long-term implications for shareholder value as both companies pivot towards a digital asset treasury model.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to mixed signals, with recent analyst downgrades and a vehicle recall contributing to immediate selling pressure. Despite this, significant community attention is focused on the highly anticipated R2 launch, which many view as a pivotal catalyst for the company's long-term success. Investors are actively debating whether current price levels represent a buying opportunity, banking on the R2 to broaden market appeal and advance Rivian's position in the competitive EV and software-defined vehicle landscape.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is garnering significant attention as analysts cite robust hyperscaler demand nearly depleting its server CPU supply and improved yields for its advanced manufacturing nodes. The community is actively discussing a major foundry customer win, which, alongside its perceived undervaluation and strategic role in domestic chip production, is fueling strong sentiment for a long-term turnaround.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amidst intense buyout speculation, driven by its established product, promising pipeline, and the biotech sector's active M&A environment. The community is keenly awaiting clarity on the company's strategic future, particularly updates on its AUR200 Phase 2 indications, even as frustration mounts over perceived management silence and recent patent developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Buys Global Rights To Preclinical Cancer Therapy For $357M

In preclinical studies, the ADC was effective at shrinking tumors without causing a proportional increase in significant side effects, even at higher doses, GSK said. 

Equity

The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

EA Series Trust - Altrius Global Dividend ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$39.77
Prev Close	$39.76
Open	$39.83
Dividend Yield	N/A
50-Day Moving Average	$38.11
Beta	N/A
Avg. Volume	2,545.50
PE Ratio	N/A

52-Week High	$39.83
52-Week Low	$30.48
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DIVD
EA Series Trust - Altrius Global Dividend ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DIVD News

DIVDEA Series Trust - Altrius Global Dividend ETF